Randomized Controlled Trial of Rabeprazol Versus Placebo Administration in the Prevention of Esophageal Variceal Bleeding After Esophageal Variceal Ligation

Randomized Controlled Trial of Rabeprazol Versus Placebo Administration in the Prevention of Esophageal Variceal Bleeding After Esophageal Variceal Ligation - POST-EVL Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003913

Enrollment

Registered

2010-07-15

Start date

2007-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients after esophageal variceal ligation (EVL)

Interventions

Rabeprazol Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Liver cirrhosis, Child A or B, (2)Esophageal variceal ligation within three months, (3)Confirmed F0 or F1 variceal form, without red color sign,

Exclusion criteria

Exclusion criteria: (1)Hepatocellular carcinoma (2)Refractory ascites and uncontrolled hepatic encephalopathy (3)Active alcoholism before 3 months (4)Portal thrombus (5)Allergy or past adverse reaction to proton pump inhibitors

Design outcomes

Primary

Measure	Time frame
Non-bleeding survival time	—

Countries

Japan

Contacts

Public ContactHisashi Hidaka

Kitasato University East Hospital Department of Gastroenterology, Internal Medicine

hisashi7@kitasato-u.ac.jp042-748-9111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026